Mimetogen Pharmaceuticals Inc. Announces Issuance of Key US Patent Protecting the Use of MIM-D3 to Treat Dry Eye Syndrome

Montreal, Canada – Mimetogen Pharmaceuticals Inc. today announced that the United States Patent & Trademark Office has issued a key patent covering the use of MIM-D3, a first in class small molecule TrkA agonist, to treat dry eye disease. US Patent No. 8,293,713 B2 entitled ‘Beta-Turn Peptidomimetic Cyclic Compounds for Treating Dry Eye’ covers the use of any composition of MIM-D3 regardless of the specific formulation.

The US patent term will expire in July 2029. "As we continue to move towards possible marketing approval of MIM-D3 to treat dry eye disease this patent adds key additional IP protection for a potentially valuable portfolio," commented Garth Cumberlidge, Ph.D., CEO of Mimetogen. "This patent represents a significant step in protecting the market potential of our current and anticipated product programs and thereby further developing shareholder value." MIM-D3 is a small molecule mimetic of nerve growth factor (NGF) that binds specifically to the TrkA receptor. NGF is a naturally occurring protein in the eyes that is responsible for the maintenance of corneal nerves and epithelium, mucin and tear production. In contrast to most other products in development or on the market, MIM-D3 is designed to quickly and directly improve the quality of the tears produced by the eyes while also reducing clinical signs and symptoms of dry eye, such as chronic dryness and grittiness. Mimetogen has completed a Phase 2 randomized, double-masked, multi-center, placebo-controlled trial designed to evaluate the safety, tolerability and efficacy of MIM-D3 in improving both the signs and symptoms of dry eye disease. The Company previously reported top line results from the study in which MIM-D3 demonstrated significant improvements (p≤0.05) in signs and symptoms of dry eye with both low (1%) and high (5%) doses and presented excellent safety and tolerability profiles. Dry eye disease is one of the most common ophthalmic problems, with an estimated 30 million people in North America suffering from it and a worldwide prevalence closely paralleling that of the United States.

About Dry Eye
Dry eye is a chronic multifactorial disease of the tears, the ocular surface and the adjacent neurological tissue that results in symptoms of discomfort, visual disturbance and tear film instability that may lead to permanent damage and scars to the ocular surface.

About Mimeotgen
Mimetogen Pharmaceuticals, Inc. is a private company focused on developing the use of peptidomimetics as a novel approach to treating ophthalmic diseases with high unmet medical needs. The underlying technology was developed at McGill University and the Lady Davis Institute for Medical Research in Montreal. The Company is currently developing novel therapeutic approaches for indications including dry eye disease, glaucoma and other degenerative diseases of the retina.